SAGE Therapeutics Inc Corporate Call - ECNP Encore Presentation: Zuranolone Data Review Summary

The following is excerpted from the question-and-answer section of the transcript.

Question: Sumant Satchidanand Kulkarni - Canaccord Genuity Corp., Research Division - Analyst : This is for Dr. Clayton. What are some of the key parameters that you think will be important for clinicians to gauge in new patients who you might start on zuranolone as an episodic monotherapy? And for continuing patients, is it your preference to switch to an episodic monotherapy or add as an adjunctive?

Question: Sumant Satchidanand Kulkarni - Canaccord Genuity Corp., Research Division - Analyst : Exactly. Anita Clayton Sure. So I don't know who wouldn't want to get better fast. I mean that's been one of the issues with regard to antidepressants. And then sustaining that is the thing that I think would make a difference in terms of whether we augment it essentially or added a treatment or we repeated this treatment. And frankly, with me and my family, I would want to get this treatment. I would want it repeated if I fell in that 70% -- well, in this 55% who required more than 1 treatment. Although 3% of people only required 1 additional treatment. This is really different than, say, other rapidly acting medications available where they have to be repeated very often, weekly or biweekly. Or, for example, transcranial magnetic stimulation, we're finding we have to repeat those treatments, which are 6 weeks of 5-days-a-week treatment. So I think as those are in treatment-resistant depression now, so that is a slightly different population. But that would be on my mind, too. We've not studied it in treatment-resistant depression but for people who are struggling with REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.